Sunovion pays $624M for Canada’s Cynapsus, lead PhIII Parkinson’s med

Sunovion Pharmaceuticals is to pay a 120% premium to buy out Canadian biotech Cynapsus Therapeutics as it looks to get its hands on the company’s late-stage Parkinson’s disease candidate.

Cynapsus ($CYNA) closed before the deal was announced at just over $18 a share, with Sunovion putting $40.50 a share, or $624 million, down for the drugmaker--a 120% premium over its closing price.

What’s the money going on? Predominately, its Phase III candidate, APL-130277, which is being tested as a sublingual thin film of apomorphine to manage so-called "off" episodes associated with PD, which see a major decrease in mobility.

Case Study

[Case Study] Clinical Supply Management

Download this case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study.

A pivotal Phase III trial is ongoing, but if successful, the company expects to file for an NDA for APL-130277 in the U.S. in the first half of next year.

A pivotal European clinical program which is looking at the safety and efficacy of APL-130277 in PD patients is also expected to begin in the fourth quarter of 2016--the same period the merger deal should be formally signed and sealed.

“Parkinson’s disease is a chronic, progressive neurodegenerative disease that affects more than four million people around the world, and there is a significant need for new options to treat the OFF episodes associated with it,” said Nobuhiko Tamura, chairman and CEO of Sunovion.

“We believe that APL-130277 is a novel late-stage candidate with the potential to make a real difference for patients and their families.”

Anthony Giovinazzo, president and CEO at Cynapsus, added: “With its leadership in therapies for central nervous system disorders and commercial experience specific to neurology, we believe Sunovion is best suited to advance APL-130277 in the United States and other key markets.

“This transaction culminates years of dedicated work by the Cynapsus team and represents significant value creation for our security holders.”

Suggested Articles

Prenatal blood test developer Cradle Genomics has secured $17.1 million to help build out its laboratory operations.

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.